Horizon Therapeutics Public Stock Price, News & Analysis (NASDAQ:HZNP)

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Horizon Therapeutics Public in the last twelve months. There are currently 7 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" HZNP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HZNP, but not buy additional shares or sell existing shares.
View HZNP analyst ratings or view top-rated stocks.

7 Wall Street analysts have issued 1 year price targets for Horizon Therapeutics Public's stock. Their HZNP share price targets range from $110.00 to $116.50. On average, they predict the company's stock price to reach $115.20 in the next twelve months. This suggests that the stock has a possible downside of 0.9%.
View analysts price targets for HZNP or view top-rated stocks among Wall Street analysts.

Horizon Therapeutics Public Limited (NASDAQ:HZNP) posted its earnings results on Tuesday, August, 8th. The biopharmaceutical company reported $1.20 earnings per share for the quarter, topping analysts' consensus estimates of $1.12 by $0.08. The biopharmaceutical company had revenue of $945 million for the quarter, compared to analyst estimates of $873.52 million. Horizon Therapeutics Public had a net margin of 12.02% and a trailing twelve-month return on equity of 20.46%. The company's quarterly revenue was up 7.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.07 EPS.

ETFs with the largest weight of Horizon Therapeutics Public (NASDAQ:HZNP) stock in their portfolio include IQ Merger Arbitrage ETF (MNA), First Trust Merger Arbitrage ETF (MARB), AltShares Merger Arbitrage ETF (ARB), VictoryShares Nasdaq Next 50 ETF (QQQN), ProShares Merger ETF (MRGR), Invesco Nasdaq Biotechnology ETF (IBBQ), Goldman Sachs Hedge Industry VIP ETF (GVIP) and Strategas Global Policy Opportunities ETF (SAGP).

70 employees have rated Horizon Therapeutics Public Chief Executive Officer Timothy Walbert on Glassdoor.com. Timothy Walbert has an approval rating of 73% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Horizon Therapeutics Public investors own include Alibaba Group (BABA), NVIDIA (NVDA), OPKO Health (OPK), Advanced Micro Devices (AMD), Netflix (NFLX), Gilead Sciences (GILD), Tesla (TSLA), AbbVie (ABBV), Micron Technology (MU) and PayPal (PYPL).

Horizon Therapeutics Public's stock is owned by many different retail and institutional investors. Top institutional shareholders include Pentwater Capital Management LP (0.00%), Walleye Trading LLC (0.00%), Maven Securities LTD (0.00%), Soros Fund Management LLC (1.44%), Adage Capital Partners GP L.L.C. (1.28%) and Morgan Stanley (1.24%). Insiders that own company stock include Aaron Cox, Andy Pasternak, Barry Moze, Brian K Beeler, Daniel A Camardo, Elizabeth HZ Thompson, Geoffrey M Curtis, Irina Konstantinovsky, Jeffrey W Sherman, Michael A Desjardin, Michael G Grey, Miles W Mchugh, Paul W Hoelscher, Paul W Hoelscher, Sean M Clayton, Timothy P Walbert, Vikram Karnani and William F Daniel.
View institutional ownership trends.